We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
International consensus recommendations for the use of prolonged‐infusion beta‐lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists
- Authors
Hong, Lisa T.; Downes, Kevin J.; FakhriRavari, Alireza; Abdul‐Mutakabbir, Jacinda C.; Kuti, Joseph L.; Jorgensen, Sarah; Young, David C.; Alshaer, Mohammad H.; Bassetti, Matteo; Bonomo, Robert A.; Gilchrist, Mark; Jang, Soo Min; Lodise, Thomas; Roberts, Jason A.; Tängdén, Thomas; Zuppa, Athena; Scheetz, Marc H.
- Abstract
Intravenous β‐lactam antibiotics remain a cornerstone in the management of bacterial infections due to their broad spectrum of activity and excellent tolerability. β‐lactams are well established to display time‐dependent bactericidal activity, where reductions in bacterial burden are directly associated with the time that free drug concentrations remain above the minimum inhibitory concentration (MIC) of the pathogen during the dosing interval. In an effort to take advantage of these bactericidal characteristics, prolonged (extended and continuous) infusions (PIs) can be applied during the administration of intravenous β‐lactams to increase time above the MIC. PI dosing regimens have been implemented worldwide, but implementation is inconsistent. We report consensus therapeutic recommendations for the use of PI β‐lactams developed by an expert international panel with representation from clinical pharmacy and medicine. This consensus guideline provides recommendations regarding pharmacokinetic and pharmacodynamic targets, therapeutic drug‐monitoring considerations, and the use of PI β‐lactam therapy in the following patient populations: severely ill and nonseverely ill adult patients, pediatric patients, and obese patients. These recommendations provide the first consensus guidance for the use of β‐lactam therapy administered as PIs and have been reviewed and endorsed by the American College of Clinical Pharmacy (ACCP), the British Society for Antimicrobial Chemotherapy (BSAC), the Cystic Fibrosis Foundation (CFF), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the Infectious Diseases Society of America (IDSA), the Society of Critical Care Medicine (SCCM), and the Society of Infectious Diseases Pharmacists (SIDP).
- Subjects
BETA lactam antibiotics; INFECTIOUS Diseases Society of America; MEDICAL microbiology; LACTAMS; CRITICAL care medicine; COMMUNICABLE diseases; CYSTIC fibrosis; PHARMACY colleges
- Publication
Pharmacotherapy, 2023, Vol 43, Issue 8, p740
- ISSN
0277-0008
- Publication type
Article
- DOI
10.1002/phar.2842